Database : MEDLINE
Search on : myelodysplastic and syndromes [Words]
References found : 14788 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1479 go to page                         

  1 / 14788 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29097497
[Au] Autor:Ripperger T; Hofmann W; Koch JC; Shirneshan K; Haase D; Wulf G; Issing PR; Karnebogen M; Schmidt G; Auber B; Schlegelberger B; Illig T; Zirn B; Steinemann D
[Ad] Address:Department of Human Genetics, Hannover Medical School, Hannover, Germany; ripperger.tim@mh-hannover.de.
[Ti] Title:MDS1 and EVI1 complex locus ( ): a novel candidate gene for hereditary hematological malignancies.
[So] Source:Haematologica;, 2017 Nov 02.
[Is] ISSN:1592-8721
[Cp] Country of publication:Italy
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher

  2 / 14788 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29097382
[Au] Autor:Shiozawa Y; Malcovati L; Gallì A; Pellagatti A; Karimi M; Sato-Otsubo A; Sato Y; Suzuki H; Yoshizato T; Yoshida K; Shiraishi Y; Chiba K; Makishima H; Boultwood J; Hellström-Lindberg E; Miyano S; Cazzola M; Ogawa S
[Ad] Address:Department of Pediatrics, The University of Tokyo, Tokyo, Japan.
[Ti] Title:Gene expression and risk of leukemic transformation in myelodysplasia.
[So] Source:Blood;, 2017 Nov 02.
[Is] ISSN:1528-0020
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders with a highly variable prognosis. To identify a gene expression-based classification of myelodysplasia with biological and clinical relevance, we performed a comprehensive transcriptomic analysis of myeloid neoplasms with dysplasia using transcriptome sequencing. Unsupervised clustering of gene expression data of bone marrow CD34+ cells from 100 patients identified two subgroups. The first subtype was characterized by increased expression of genes related to erythroid/megakaryocytic (EMK) lineages, whereas the second subtype showed up-regulation of genes related to immature progenitor (IMP) cells. Compared to the first, so-called EMK subtype, the IMP subtype showed up-regulation of many signaling pathways and down-regulation of several pathways related to metabolism and DNA repair. The IMP subgroup was associated with a significantly shorter survival in both univariate (hazard ratio [HR] 5.0 [95% confidence interval (CI), 1.8-14], P = 0.002) and multivariate analysis (HR 4.9 [95% CI, 1.3-19], P = 0.02). Leukemic transformation was limited to the IMP subgroup. The prognostic significance of our classification was validated in an independent cohort of 183 patients. We also constructed a model to predict the subgroups using gene expression profiles of unfractionated bone marrow mononuclear cells (BMMNCs). The model successfully predicted clinical outcomes in a test set of 114 patients with BMMNC samples. Addition of our classification to the clinical model improved prediction of patient outcomes. These results indicated biological and clinical relevance of our gene expression-based classification, which will improve risk prediction and treatment stratification of MDS.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher

  3 / 14788 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29042320
[Au] Autor:Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
[Ad] Address:Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Pediatric Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
[Ti] Title:Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
[So] Source:J Control Release;268:92-101, 2017 Oct 16.
[Is] ISSN:1873-4995
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders and clonal hematopoietic stem cell disorders characterized by abnormal blood cells, or reduced peripheral blood cell count. Recent clinical studies on combination therapy of decitabine (DAC) and arsenic trioxide (ATO) have demonstrated synergy on MDS treatment, but the treatment can cause significant side effects to patients. In addition, both drugs have to be administered on a daily basis due to their short half-lives. In addressing key issues of reducing toxic side effects and improving pharmacokinetic profiles of the therapeutic agents, we have developed a new formulation by co-packaging DAC and ATO into alendronate-conjugated bone-targeting nanoparticles (BTNPs). Our pharmacokinetic studies revealed that intravenously administered BTNPs increased circulation time up to 3days. Biodistribution analysis showed that the BTNP facilitated DAC and ATO accumulation in the bone, which is 6.7 and 7.9 times more than untargeted NP. Finally, MDS mouse model treated with BTNPs showed better restoration of complete blood count to normal level, and significantly longer median survival as compared to free drugs or untargeted NPs treatment. Our results support bone-targeted co-delivery of DAC and ATO for effective treatment of MDS.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher

  4 / 14788 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29023992
[Au] Autor:Patnaik MM; Vallapureddy R; Yalniz FF; Hanson CA; Ketterling RP; Lasho TL; Finke C; Al-Kali A; Gangat N; Tefferi A
[Ad] Address:Division of Hematology, Mayo Clinic, Rochester, Minnesota.
[Ti] Title:Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.
[So] Source:Am J Hematol;, 2017 Oct 11.
[Is] ISSN:1096-8652
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Therapy related myeloid neoplasms (t-MN) including therapy related myelodysplastic syndromes (t-MDS) and acute myeloid leukemia (t-AML) are associated with aggressive disease biologies and poor outcomes. In this large (n = 497) and informative (inclusive of molecular and cytogenetic information) chronic myelomonocytic leukemia (CMML) patient cohort, we demonstrate key biological insights and an independent prognostic impact for t-CMML. T-CMML was diagnosed in 9% of patients and occurred approximately 7 years after exposure to prior chemotherapy and/or radiation therapy. In comparison to de novo CMML, t-CMML patients had higher LDH levels, higher frequency of karyotypic abnormalities and had higher risk cytogenetic stratification. There were no differences in the distribution of gene mutations and unlike t-MDS/AML, balanced chromosomal translocations, abnormalities of chromosome 11q23 (1%) and Tp53 mutations (<2%) were uncommon. Molecularly integrated CMML prognostic models were not effective in risk stratifying t-CMML patients and responses to hypomethylating agents were dismal with no complete responses. Median overall (OS) and leukemia free survival (LFS) was shorter for t-CMML in comparison to d-CMML (Median OS 10.9 vs 26 months and median LFS 50 vs 127 months) and t-CMML independently and adversely impacted OS (P = .0001 HR 2.1 95% CI 1.4-3.0). This prognostic impact was retained in the context of the Mayo Molecular Model (P = .001, HR 2.4, 95% CI 1.5-3.7) and the GFM prognostic model (P < .0001, HR 2.15, 95% CI 1.5-3.7). In summary, we highlight the unique genetics and independent prognostic impact of t-CMML, warranting its inclusion as a separate entity in the classification schema for both CMML and t-MN.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher
[do] DOI:10.1002/ajh.24939

  5 / 14788 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28892084
[Au] Autor:Scheid C; de Wreede L; van Biezen A; Koenecke C; Göhring G; Volin L; Maertens J; Finke J; Passweg J; Beelen D; Cornelissen JJ; Itälä-Remes M; Chevallier P; Russell N; Petersen E; Milpied N; Richard Espiga C; Peniket A; Sierra J; Mufti G; Crawley C; Veelken JH; Ljungman P; Cahn JY; Alessandrino EP; de Witte T; Robin M; Kröger N
[Ad] Address:Department of Medicine, University of Cologne, Cologne, Germany.
[Ti] Title:Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
[So] Source:Bone Marrow Transplant;52(11):1519-1525, 2017 Nov.
[Is] ISSN:1476-5365
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (P<0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (P<0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1709
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:In-Process
[do] DOI:10.1038/bmt.2017.171

  6 / 14788 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28757618
[Au] Autor:Zeidan AM; Sekeres MA; Barnard J; Steensma DP; Komrokji R
[Ad] Address:Section of Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.
[Ti] Title:Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?
[So] Source:Leukemia;31(11):2539-2541, 2017 Nov.
[Is] ISSN:1476-5551
[Cp] Country of publication:England
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1707
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:In-Data-Review
[do] DOI:10.1038/leu.2017.238

  7 / 14788 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28757616
[Au] Autor:Calvo X; Florensa L; Arenillas L
[Ad] Address:Laboratorio de Citología Hematológica. Servicio de Patología, GRETNHE, IMIM Hospital del Mar Research Institute, Barcelona, Spain.
[Ti] Title:Is there a pressing need for improving prognostication strategies in therapy-related myelodysplastic syndromes?
[So] Source:Leukemia;, 2017 Jul 31.
[Is] ISSN:1476-5551
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Leukemia accepted article preview online, 31 July 2017. doi:10.1038/leu.2017.237.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1707
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher
[do] DOI:10.1038/leu.2017.237

  8 / 14788 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28679999
[Au] Autor:Ito M
[Ad] Address:Department of Pathology, Japanese Red Cross Nagoya First Hospital.
[Ti] Title:Bone marrow failure in childhood: central pathology review of a nationwide registry.
[So] Source:Rinsho Ketsueki;58(6):661-668, 2017.
[Is] ISSN:0485-1439
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract:Refractory cytopenia of childhood (RCC) was proposed as a provisional entity in the 2008 WHO classification of myelodysplastic syndromes (MDS). It is defined as a childhood MDS featuring persistent cytopenia without increase blasts in bone marrow (BM) or peripheral blood (PB). Because the majority of RCC cases feature hypocellularity and pancytopenia, it is quite challenging to differentiate RCC from acquired aplastic anemia (AA) and many kinds of inherited bone marrow failure syndromes (IBMFS). Diagnosis of RCC requires BM histology of characteristic features such as isolated erythroid islet with left shift, abnormal localization and micromegakaryocytes. The Japanese Society of Pediatric Hematology/Oncology has opened the central registry review system since 2009 to evaluate childhood cases of bone marrow failure (BMF). It has reviewed cytology and BM pathology of all registered BMF cases, which number more than 1,700. In the evaluation of BMF, BM pathology is important to assess the mechanism of hematopoiesis. Pathological dysplasia should be differentiated from cytological dysplasia. A central review system is important for rare diseases, such as pediatric BMF. Standardization of pathological diagnosis should be established upon consensus findings, descriptions, and diagnostic approaches. In this review, the pathology of pediatric BMF syndromes is summarized.
[Mh] MeSH terms primary: Bone Marrow Diseases/pathology
Bone Marrow/pathology
[Mh] MeSH terms secundary: Bone Marrow Diseases/diagnosis
Bone Marrow Diseases/epidemiology
Cell Death
Child
Disease Progression
Erythrocytes/pathology
Humans
Registries
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1711
[Cu] Class update date: 171102
[Lr] Last revision date:171102
[Js] Journal subset:IM
[Da] Date of entry for processing:170706
[St] Status:MEDLINE
[do] DOI:10.11406/rinketsu.58.661

  9 / 14788 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28679998
[Au] Autor:Iwama A
[Ad] Address:Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University.
[Ti] Title:Deregulated polycomb complex function in the pathogenesis of MDS.
[So] Source:Rinsho Ketsueki;58(6):654-660, 2017.
[Is] ISSN:0485-1439
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract:Epigenetic regulation holds a key role in gene expression due to its modulation of the structure and function of chromatin. Notably, epigenetic dysregulation is deeply involved in the pathogenesis of hematological malignancies. Polycomb group (PcG) genes encoding histone modifier proteins are representative epigenetic genes that regulate a variety of cellular functions, including self-renewal and multi-lineage differentiation of stem cells. Surprisingly, many PcG genes are targeted by deletions or somatic mutations or both in a number of hematological malignancies, such as myelodysplastic syndrome (MDS). PcG proteins form multiprotein complexes and exert either oncogenic or tumor-suppressive functions, depending on the tumor type. In MDS, they function as tumor suppressors. This review summarizes the current knowledge on deregulated polycomb function in the pathogenesis of MDS.
[Mh] MeSH terms primary: Myelodysplastic Syndromes/metabolism
Polycomb-Group Proteins/metabolism
[Mh] MeSH terms secundary: Animals
Bone Marrow Cells/metabolism
Histones/metabolism
Humans
Multigene Family
Myelodysplastic Syndromes/genetics
Neoplasms/genetics
Neoplasms/metabolism
Polycomb-Group Proteins/genetics
Protein Binding
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Histones); 0 (Polycomb-Group Proteins)
[Em] Entry month:1711
[Cu] Class update date: 171102
[Lr] Last revision date:171102
[Js] Journal subset:IM
[Da] Date of entry for processing:170706
[St] Status:MEDLINE
[do] DOI:10.11406/rinketsu.58.654

  10 / 14788 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28679990
[Au] Autor:Kudo D; Shimizu M; Kuroda A; Suyama T; Shinagawa A; Ito S
[Ad] Address:Department of Hematology/Oncology, Hitachi General Hospital.
[Ti] Title:Myelodysplastic syndrome with neutrophilic dermatosis successfully treated with azacitidine.
[So] Source:Rinsho Ketsueki;58(6):607-612, 2017.
[Is] ISSN:0485-1439
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract:A 66-year-old male underwent prednisolone (PSL) therapy of 13 mg/day for rheumatoid arthritis (RA). Antiphospholipid antibody syndrome, neutrophilic dermatosis (ND), and myelodysplastic syndrome (MDS) developed. Treatment of MDS required red cell concentrate transfusion, and second courses of azacitidine therapy (75 mg/m daily, intravenous injection for 7 consecutive days) led to hematologic remission. Furthermore, ND improved early after the start of azacitidine therapy, making it possible to decrease the dose of PSL. After 12th courses of azacitidine therapy, treatment was discontinued and the long-term remission of MDS and ND has been maintained. During the course, the level of matrix metalloproteinase-3, as a marker of RA, also decreased. There are few case reports of MDS in which azacitidine was effective for autoimmune diseases, including ND. We report the present case.
[Mh] MeSH terms primary: Azacitidine/therapeutic use
Myelodysplastic Syndromes/drug therapy
Sweet Syndrome/complications
[Mh] MeSH terms secundary: Aged
Humans
Male
Myelodysplastic Syndromes/complications
Sweet Syndrome/pathology
Treatment Outcome
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:M801H13NRU (Azacitidine)
[Em] Entry month:1711
[Cu] Class update date: 171102
[Lr] Last revision date:171102
[Js] Journal subset:IM
[Da] Date of entry for processing:170706
[St] Status:MEDLINE
[do] DOI:10.11406/rinketsu.58.607


page 1 of 1479 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information